Amgen (AMGN) Depreciation & Amortization (CF) (2009 - 2026)

Amgen (AMGN) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 19.54% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.9 billion (down 12.26% YoY), while the FY2025 annual figure was $5.2 billion, down 7.6% from the prior year.
• Depreciation & Amortization (CF) came in at $1.1 billion for Q1 2026 at Amgen, down from $1.1 billion in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.4 billion in Q2 2024, with the low at $828.0 million in Q2 2022.
• Average Depreciation & Amortization (CF) over 5 years is $1.1 billion, with a median of $1.1 billion recorded in 2025.
• Across the five-year window, Depreciation & Amortization (CF) jumped 56.25% in 2024 and retreated 19.54% in 2026, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $911.0 million in 2022, then jumped by 51.48% to $1.4 billion in 2023, then climbed by 1.23% to $1.4 billion in 2024, then decreased by 18.97% to $1.1 billion in 2025, then decreased by 1.41% to $1.1 billion in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.1 billion, $1.1 billion, and $1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.